

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**REVOCATION OF PRIOR POWERS OF ATTORNEY
and
NEW POWER OF ATTORNEY**

Sir:

The undersigned, Millennium Pharmaceuticals, Inc., a Delaware Corporation, assignee of the entire right, title and interest for all of the patents and patent applications identified in the attached Schedule A, hereby revokes all previous powers of attorney or authorizations of agent given in the identified patents and patent applications and in any divisional, continuing, substitute, renewal, reexamination, or reissue applications thereof, and appoints all practitioners of Lowrie, Lando & Anastasi, LLP associated with Customer Number:

37462


as assignee's attorneys or agents with full power of substitution to take any and all action necessary with regard to the identified patents and patent applications, and with regard to any divisional, continuing, substitute, renewal or reissue applications thereof.

Please address all telephone calls to Laurie Butler Lawrence at telephone no. (617) 395-7000.

Please forward all correspondence to the correspondence address associated with Customer Number:

37462

Millennium Pharmaceuticals Inc.

By: 
Name: James D. Darnley Jr.
Title: Vice President & Chief IP Counsel

Dated: 3 APR 1 2008

ASSIGNEE CERTIFICATION

Attached to this power is a Certificate Under 37 CFR 3.73(b).

Dated: 4/11/08

/Laurie Butler Lawrence/
Laurie Butler Lawrence, Reg. No. 46,593
LOWRIE, LANDO & ANASTASI, LLP
Riverfront Office Park
One Main Street
Cambridge, MA 02142
(617) 395-7000

SCHEDULE A**U.S. Patents:**

<u>U.S. PATENT NO.</u>	<u>ISSUE DATE</u>	<u>ATTORNEY'S DOCKET NO.</u>
7,053,202	05/30/06	M2051-701310
6,312,689	11/06/01	M2051-701419
6,458,353	10/01/02	M2051-701440
6,491,915	12/10/02	M2051-701441
6,406,694	06/18/02	M2051-701442
6,406,865	06/18/02	M2051-701444
6,448,021	09/10/02	M2051-701445
6,451,522	09/17/02	M2051-701446
6,395,497	05/28/02	M2051-701510
6,352,832	03/05/02	M2051-701619
6,727,349	04/27/04	M2051-701730
6,696,550	02/24/04	M2051-701830

SCHEDULE A**U.S. Patent Applications:**

<u>U.S. APPLICATION NO.</u>	<u>FILING DATE</u>	<u>ATTORNEY'S DOCKET NO.</u>
10/736,112	12/15/03	M2051-700410
11/027,954	12/30/04	M2051-700919
11/536,339	9/28/06	M2051-700920
60/535,260	1/9/04	M2051-700900
11/130,543	5/16/05	M2051-701010
11/725,252	3/19/07	M2051-701020
60/571,382	5/14/04	M2051-701000
10/733,563	12/10/03	M2051-701219
11/318,969	12/27/05	M2051-701320
60/350,166	10/19/01	M2051-701300
60/392,364	6/26/02	M2051-701301
09/898,513	7/3/01	M2051-701420
10/656,805	9/2/03	M2051-701421
10/826,454	4/16/04	M2051-701422
11/924,091	10/25/07	M2051-701720
11/924,153	10/25/07	M2051-701721
11/924,783	10/26/07	M2051-701722
11/924,794	10/26/07	M2051-701723
11/925,080	10/26/07	M2051-701724
10/766,773	1/27/04	M2051-701740
10/766,610	1/27/04	M2051-701840

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Millennium Pharmaceuticals, Inc.Application No./Patent No.: 10/766,610 Filed/Issue Date: 1/27/04Entitled: HUMANIZED ANTI-CCR2 ANTIBODIES AND METHODS OF USE THEREFOR

Millennium Pharmaceuticals, Inc., a Corporation
 (Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest
 (The extent (by percentage) of its ownership interest is _____ %)

in the patent application/patent identified above by virtue of either:

A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: inventor(s) To: Millennium Pharmaceuticals, Inc.
 The document was recorded in the United States Patent and Trademark Office at
 Reel 012511, Frame 0380, or for which a copy thereof is attached.
2. From: inventor(s) To: Medical Research Council Technology
 The document was recorded in the United States Patent and Trademark Office at
 Reel 012511, Frame 0350, or for which a copy thereof is attached.
3. From: Medical Research Council Technology To: Millennium Pharmaceuticals, Inc.
 The document was recorded in the United States Patent and Trademark Office at
 Reel 012511, Frame 0448, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☒ As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

/Laurie Butler Lawrence/

 Signature
Laurie Butler Lawrence

 Printed or Typed Name

 Patent Attorney

 Title

4/12/08

 Date
617-395-7000

 Telephone Number

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.